Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study

Autor: Giorgio Franco, Benedetto Torrisi, Sebastiano Cimino, T. Tony Cai, Mauro Silvani, Giovanna Russo, Maurizio Madonia, Paolo Verze, Giuseppe D'Achille, Giovanni Liguori, Salvatore Privitera, Alessandro Palmieri, Vincenzo Favilla, G. Siracusa, Giuseppe Morgia, Giorgio Cavallini, Alessandro Zucchi, Vincenzo Mirone
Přispěvatelé: Favilla, V., Russo, G. I., Zucchi, A., Siracusa, G., Privitera, S., Cimino, S., Madonia, M., Cai, T., Cavallini, G., Liguori, G., D'Achille, G., Silvani, M., Franco, G., Verze, P., Palmieri, A., Torrisi, B., Mirone, V., Morgia, G., Madonia, Maurizio
Rok vydání: 2016
Předmět:
Male
verapamil
Time Factors
hyaluronic acid
intralesional therapy
Peyronie's disease
Endocrinology
Diabetes and Metabolism
Reproductive Medicine
Endocrinology
Urology
Penile Induration
030232 urology & nephrology
Injections
Intralesional
Group A
Group B
law.invention
chemistry.chemical_compound
0302 clinical medicine
hyaluronic acid
intralesional therapy
Peyronie's disease
verapamil
Randomized controlled trial
law
Hyaluronic acid
Adult
Aged
Double-Blind Method
Humans
Hyaluronic Acid
Injections
Intralesional
Italy
Middle Aged
Penile Erection
Penis
Prospective Studies
Recovery of Function
Treatment Outcome
Urological Agents
Verapamil
Diabetes and Metabolism
Prospective cohort study
medicine.anatomical_structure
030220 oncology & carcinogenesis
medicine.drug
Human
medicine.medical_specialty
Time Factor
03 medical and health sciences
medicine
Urological Agent
business.industry
medicine.disease
Peni
Surgery
Prospective Studie
chemistry
business
Zdroj: Andrology. 5(4)
ISSN: 2047-2927
Popis: Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD). This is a multi-centre prospective double-arm, randomized, double-blinded study comparing ILVI vs. intralesional HA after 12-weeks. Sexually active men, older than 18 years and affected by the acute phase of PD were eligible for this study. Patients have been double-blinded randomly divided into two groups (1 : 1 ratio): Group A received intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks, while group B received intralesional treatment with HA (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks. The primary efficacy outcome was the change from the baseline to the endpoint (12 weeks after therapy) for the penile curvature (degree). The secondary outcome was the change in the plaque size and in the International Index of erectile Function (IIEF-5) score. The difference between post- and pre-treatment plaque size was -1.36 mm (SD ± 1.27) for Group A and -1.80 mm (SD ± 2.47) for Group B (p-value = NS). IIEF-5 increased of 1.46 points (SD ± 2.18) in Group A and 1.78 (SD ± 2.48) in Group B (p-value ± NS). No difference in penile curvature was observed in Group A, while in Group B the penile curvature decreased of 4.60° (SD ± 5.63) from the baseline (p
Databáze: OpenAIRE
Externí odkaz: